BioMarin Pharmaceutical Inc
BMRNHealthcare|Biotechnology|USA
$56.02
-0.20 (-0.35%)
DCF (FCF)
$37.55
Tangible Book
$29.52
Graham Number
$45.74
Earnings Power
$19.68
About
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.
Stock Price
-16.7%(1Y)
Pipeline Summary
176 total trials29
Phase 1
53
Phase 2
33
Phase 3
10
Phase 4
Completed: 102ENROLLING_BY_INVITATION: 4Terminated: 26Unknown: 5Recruiting: 16NOT_YET_RECRUITING: 2Active: 12Withdrawn: 5NO_LONGER_AVAILABLE: 1APPROVED_FOR_MARKETING: 3
Active Trials (28)
Study of BMN 349 Single Dose in PiZZ and PiMZ/MASH Adult Participants
NCT06738017Alpha 1-Antitrypsin Deficiency
Phase 1Recruiting
Enrollment: 12 participants
A Study of Vosoritide Versus Placebo in Children With Hypochondroplasia Aged 0 to < 36 Months
NCT07126262Hypochondroplasia
Phase 2Recruiting
Enrollment: 60 participants
Rapid Drug Desensitization Study in Adults Experiencing Hypersensitivity Reactions to Palynziq
NCT06780332Phenylketonuria
Phase 4Active
Enrollment: 9 participants
An Extension Study to Evaluate the Efficacy and Safety of BMN 111 in Children With Achondroplasia
NCT03424018Achondroplasia
Phase 3Active
Enrollment: 119 participants
An Extension Study to Evaluate Safety and Efficacy of BMN 111 in Children With Achondroplasia
NCT03989947Achondroplasia
Phase 2Active
Enrollment: 73 participants
BioScore
6.6/10
Buy
Ownership
Recent Insider Trades
Guyer Charles GregSELL
2026-03-1116,486 shares @ $60.46
Friberg Gregory RSELL
2026-02-266,326 shares @ $60.38
Davis George EricSELL
2026-02-2626,061 shares @ $61.36
Burkhart ErinSELL
2025-05-201,786 shares @ $59.31
Hubbard CristinSELL
2025-05-02273 shares @ $64.92
Recent News
2026-03-16 17:25:53
2026-03-16 13:55:24
2026-03-16 13:29:48
2026-03-13 02:00:32
2026-03-12 13:35:56
Data last updated: Apr 7, 2026, 02:29 PM